The company is advancing its lead program into clinical testing with a Phase 1/2 trial planned to enroll about two dozen volunteers.
Company Description
Arbor Biotechnologies is developing gene editing therapies for rare diseases, specifically targeting primary hyperoxaluria type 1 with its lead program ABO-101, which aims to provide a one-time treatment solution.